Journal of Pharmacovigilance

Design and production of PE38-EGFR immunotoxin against tumors

9^th International Conference and Exhibition on Pharmacovigilance & Drug Safety

July 17-18, 2017 Munich, Germany

Behzad Baradaran, Jafar Majidi and Safar Farajnia

Tabriz University of Medical Sciences, Iran

Posters & Accepted Abstracts: J Pharmacovigil

Abstract:

Introduction & Aim: Growth and progression of tumors depends largely on the activity of cell membrane receptors like epidermal growth factor receptor (EGFR). Epidermal growth factor receptor (EGFR) plays an important role in the growth and survival of many solid tumors and it is an encouraging target for cancer treatment. Immunotherapy is the best strategy in cancer treatment and immunotoxins have predominant position herein. Aim of this study is design and production of PE38-EGFR immunotoxin against tumors. Materials & Methods: For production of monoclonal antibody against human EGFR, first six female Balb/c mice six to eight weeks old were immunized against A431 tumoral cells that express more EGFR on its membrane in four periods. Large scales of monoclonal antibodies were produced in vitro and their effects on A431 cells were evaluated. For production of recombinant toxin PE38, toxin gene was cloned in the vector. The recombinant vector was transformed to E. coli bacterium by electrical shock. The production of toxin was induced by IPTG and then, produced toxin was purified by nickel column. The toxin was conjugated with antibody by chemical method. The effects of immunotoxin in induction of apoptosis on tumoral cells were assayed by ELISA method. Results: In this study, four monoclones with absorbance about 1.5 were selected. MTT assay showed that monoclonal antibodies produced against EGFR prevented 35% of A431 cell growth in culture in comparison with control group. The immunotoxin induced 62% apoptosis in tumoral cells as well as. Conclusion: These results indicate that the monoclonal antibodies produced against EGFR and developed immunotoxin may be used in treatment of tumors with membranous EGFR if produced in recombinant forms.

Biography :

Email: behzad_im@yahoo.com